Thrombosis and Drug-Eluting Stents. An Objective Appraisal

David Holmes, Dean J. Kereiakes, Warren K. Laskey, Antonio Colombo, Stephen G. Ellis, Timothy D. Henry, Jeffrey J. Popma, Patrick W.J.C. Serruys, Takeshi Kimura, David O. Williams, Stephan Windecker, Mitchell W. Krucoff

Research output: Contribution to journalReview article

109 Citations (Scopus)

Abstract

Stent thrombosis (ST) after percutaneous coronary intervention has been the focus of intense interest because of its attendant morbidity and mortality. There is controversy about several facets of the problem. These include the frequency of ST with drug-eluting stents (DES) versus bare-metal stents (BMS), the timing of the event, clinical consequences, risk factors, adjunctive therapy, and new preventive approaches. Information has accrued rapidly from several sources, including randomized controlled clinical trials of DES versus BMS in carefully selected subsets of patients and registry experiences in larger patient groups, which provide a more universal real-world picture. The results from these different data sets are not completely concordant. However, several general conclusions can be made: 1) ST is an infrequent but very severe complication of both BMS and DES; 2) at the present time, during 4 years of follow-up from randomized controlled trials that compared DES and BMS, there is no apparent difference in overall ST frequency, although the time course for occurrence appears to differ, with a relative numeric excess of ST late after DES implant; 3) despite this relative imbalance, no differences in the end points of death or death and infarction between DES and BMS are observed; 4) longer-term follow-up of these patients as well as larger angiographic and clinical subsets of patients who receive this technology outside of randomized trials are required to fully study this issue; and 5) advances in stent platforms for drug elution as well as adjunctive pharmacologic therapy are being evaluated to enhance long-term safety.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalJournal of the American College of Cardiology
Volume50
Issue number2
DOIs
StatePublished - Jul 10 2007

Fingerprint

Drug-Eluting Stents
Stents
Thrombosis
Metals
Randomized Controlled Trials
Percutaneous Coronary Intervention
Infarction
Registries
Technology
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Holmes, D., Kereiakes, D. J., Laskey, W. K., Colombo, A., Ellis, S. G., Henry, T. D., ... Krucoff, M. W. (2007). Thrombosis and Drug-Eluting Stents. An Objective Appraisal. Journal of the American College of Cardiology, 50(2), 109-118. https://doi.org/10.1016/j.jacc.2007.04.032

Thrombosis and Drug-Eluting Stents. An Objective Appraisal. / Holmes, David; Kereiakes, Dean J.; Laskey, Warren K.; Colombo, Antonio; Ellis, Stephen G.; Henry, Timothy D.; Popma, Jeffrey J.; Serruys, Patrick W.J.C.; Kimura, Takeshi; Williams, David O.; Windecker, Stephan; Krucoff, Mitchell W.

In: Journal of the American College of Cardiology, Vol. 50, No. 2, 10.07.2007, p. 109-118.

Research output: Contribution to journalReview article

Holmes, D, Kereiakes, DJ, Laskey, WK, Colombo, A, Ellis, SG, Henry, TD, Popma, JJ, Serruys, PWJC, Kimura, T, Williams, DO, Windecker, S & Krucoff, MW 2007, 'Thrombosis and Drug-Eluting Stents. An Objective Appraisal', Journal of the American College of Cardiology, vol. 50, no. 2, pp. 109-118. https://doi.org/10.1016/j.jacc.2007.04.032
Holmes, David ; Kereiakes, Dean J. ; Laskey, Warren K. ; Colombo, Antonio ; Ellis, Stephen G. ; Henry, Timothy D. ; Popma, Jeffrey J. ; Serruys, Patrick W.J.C. ; Kimura, Takeshi ; Williams, David O. ; Windecker, Stephan ; Krucoff, Mitchell W. / Thrombosis and Drug-Eluting Stents. An Objective Appraisal. In: Journal of the American College of Cardiology. 2007 ; Vol. 50, No. 2. pp. 109-118.
@article{2beed2a960b646f5bdff074d4a8405b6,
title = "Thrombosis and Drug-Eluting Stents. An Objective Appraisal",
abstract = "Stent thrombosis (ST) after percutaneous coronary intervention has been the focus of intense interest because of its attendant morbidity and mortality. There is controversy about several facets of the problem. These include the frequency of ST with drug-eluting stents (DES) versus bare-metal stents (BMS), the timing of the event, clinical consequences, risk factors, adjunctive therapy, and new preventive approaches. Information has accrued rapidly from several sources, including randomized controlled clinical trials of DES versus BMS in carefully selected subsets of patients and registry experiences in larger patient groups, which provide a more universal real-world picture. The results from these different data sets are not completely concordant. However, several general conclusions can be made: 1) ST is an infrequent but very severe complication of both BMS and DES; 2) at the present time, during 4 years of follow-up from randomized controlled trials that compared DES and BMS, there is no apparent difference in overall ST frequency, although the time course for occurrence appears to differ, with a relative numeric excess of ST late after DES implant; 3) despite this relative imbalance, no differences in the end points of death or death and infarction between DES and BMS are observed; 4) longer-term follow-up of these patients as well as larger angiographic and clinical subsets of patients who receive this technology outside of randomized trials are required to fully study this issue; and 5) advances in stent platforms for drug elution as well as adjunctive pharmacologic therapy are being evaluated to enhance long-term safety.",
author = "David Holmes and Kereiakes, {Dean J.} and Laskey, {Warren K.} and Antonio Colombo and Ellis, {Stephen G.} and Henry, {Timothy D.} and Popma, {Jeffrey J.} and Serruys, {Patrick W.J.C.} and Takeshi Kimura and Williams, {David O.} and Stephan Windecker and Krucoff, {Mitchell W.}",
year = "2007",
month = "7",
day = "10",
doi = "10.1016/j.jacc.2007.04.032",
language = "English (US)",
volume = "50",
pages = "109--118",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Thrombosis and Drug-Eluting Stents. An Objective Appraisal

AU - Holmes, David

AU - Kereiakes, Dean J.

AU - Laskey, Warren K.

AU - Colombo, Antonio

AU - Ellis, Stephen G.

AU - Henry, Timothy D.

AU - Popma, Jeffrey J.

AU - Serruys, Patrick W.J.C.

AU - Kimura, Takeshi

AU - Williams, David O.

AU - Windecker, Stephan

AU - Krucoff, Mitchell W.

PY - 2007/7/10

Y1 - 2007/7/10

N2 - Stent thrombosis (ST) after percutaneous coronary intervention has been the focus of intense interest because of its attendant morbidity and mortality. There is controversy about several facets of the problem. These include the frequency of ST with drug-eluting stents (DES) versus bare-metal stents (BMS), the timing of the event, clinical consequences, risk factors, adjunctive therapy, and new preventive approaches. Information has accrued rapidly from several sources, including randomized controlled clinical trials of DES versus BMS in carefully selected subsets of patients and registry experiences in larger patient groups, which provide a more universal real-world picture. The results from these different data sets are not completely concordant. However, several general conclusions can be made: 1) ST is an infrequent but very severe complication of both BMS and DES; 2) at the present time, during 4 years of follow-up from randomized controlled trials that compared DES and BMS, there is no apparent difference in overall ST frequency, although the time course for occurrence appears to differ, with a relative numeric excess of ST late after DES implant; 3) despite this relative imbalance, no differences in the end points of death or death and infarction between DES and BMS are observed; 4) longer-term follow-up of these patients as well as larger angiographic and clinical subsets of patients who receive this technology outside of randomized trials are required to fully study this issue; and 5) advances in stent platforms for drug elution as well as adjunctive pharmacologic therapy are being evaluated to enhance long-term safety.

AB - Stent thrombosis (ST) after percutaneous coronary intervention has been the focus of intense interest because of its attendant morbidity and mortality. There is controversy about several facets of the problem. These include the frequency of ST with drug-eluting stents (DES) versus bare-metal stents (BMS), the timing of the event, clinical consequences, risk factors, adjunctive therapy, and new preventive approaches. Information has accrued rapidly from several sources, including randomized controlled clinical trials of DES versus BMS in carefully selected subsets of patients and registry experiences in larger patient groups, which provide a more universal real-world picture. The results from these different data sets are not completely concordant. However, several general conclusions can be made: 1) ST is an infrequent but very severe complication of both BMS and DES; 2) at the present time, during 4 years of follow-up from randomized controlled trials that compared DES and BMS, there is no apparent difference in overall ST frequency, although the time course for occurrence appears to differ, with a relative numeric excess of ST late after DES implant; 3) despite this relative imbalance, no differences in the end points of death or death and infarction between DES and BMS are observed; 4) longer-term follow-up of these patients as well as larger angiographic and clinical subsets of patients who receive this technology outside of randomized trials are required to fully study this issue; and 5) advances in stent platforms for drug elution as well as adjunctive pharmacologic therapy are being evaluated to enhance long-term safety.

UR - http://www.scopus.com/inward/record.url?scp=34347242071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347242071&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2007.04.032

DO - 10.1016/j.jacc.2007.04.032

M3 - Review article

C2 - 17616294

AN - SCOPUS:34347242071

VL - 50

SP - 109

EP - 118

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -